AI in healthcare is moving faster than policy. This new U.S. standard says one thing very clearly: if a hospital or health system uses AI in day-to-day work, leadership must own the risk, track each tool, review vendors, test tools locally, and watch performance after launch.
Here’s the article in plain English:
- ANSI/HSI 2800:2025 is the first American National Standard focused on AI governance in healthcare work outside just medical devices.
- It applies across clinical and admin use, including scheduling, revenue cycle, contact centers, staffing, supply chain, and predictive tools.
- It treats AI as an enterprise risk issue, with board oversight and CEO accountability.
- It expects a documented AI inventory, approval process, local validation, audit trails, and rules for retirement.
- It fits alongside NIST AI RMF and ISO/IEC 42001, but it is built for healthcare settings.
- It pushes teams to score AI risk using the same factors across use cases, such as data sensitivity, autonomy, workflow impact, and effect on care or revenue.
- It also puts pressure on vendor review: BAAs, subprocessor checks, training-data limits, audit rights, and change control all matter.
- After launch, teams still need monitoring for drift, subgroup impact, workflow problems, security events, and vendor compliance.
- The article also points to a gap in the market: 84% of healthcare groups have an AI committee, but only 12% have a formal framework, and 59% lack a documented approval process before go-live.
If I had to boil the whole piece down to one line, it would be this: healthcare AI can’t sit in a side project anymore; it needs the same board-level control, records, and review discipline as other top-risk systems.
The rest of the article explains how to turn that idea into day-to-day governance steps.
Healthcare AI Governance Gap: By the Numbers (ANSI/HSI 2800:2025)
Core Governance Requirements: Accountability, Oversight, and Decision Rights
Assign Senior Ownership and Committee Oversight
With scope in place, the next step is simple: someone has to own this.
ANSI/HSI 2800:2025 puts AI governance at the leadership level, with board oversight and CEO accountability for AI execution and compliance [1]. Put plainly, the board oversees AI governance, and the CEO is on the hook for execution and compliance [1].
In day-to-day terms, that usually means setting up a formal AI Governance Committee with actual decision rights. Not a committee that meets, nods, and disappears. A committee that can make calls.
Typical members include leaders from:
- Clinical
- Security
- Privacy
- Compliance
- Quality
- Legal
- Medical
What makes a committee work isn't the org chart. It's escalation authority. The group should have written authority to pause or change an AI deployment if safety, performance, or compliance issues show up [1].
Clinical oversight matters for a reason. AI can shape patient safety, workflow reliability, and trust. If a tool affects care, the people closest to care need a seat at the table.
Document Policies, Use Cases, and Approval Criteria
Once ownership is clear, the standard expects proof on paper.
ANSI/HSI 2800 calls for a complete AI inventory: every tool in use, even the ones tucked inside EHR updates or rolled out by a department without formal IT review. For each tool, document its purpose, users, data inputs, outputs, integrations, validation, and fallback behavior [5][6].
Policies also need to cover patient consent, privacy, algorithmic transparency, and mitigation of algorithmic bias [5][6]. And the paper trail matters just as much as the policy itself. Approval records should show local validation on the organization's own patient population, not just a vendor deck or marketing claim.
An organization should be able to show:
- What it uses
- Who approved it
- How it was validated locally
- How performance is monitored [6]
That point is easy to miss, but it's a big one. Unapproved use of consumer AI tools can slip around privacy review, BAA controls, and approved procurement.
A full inventory gives you the base layer for risk review, vendor review, and monitoring.
Map Standard Requirements to Existing Governance Programs
The fastest route to alignment is usually the least flashy one: plug these duties into programs that already exist.
The practical path to compliance is not building a brand-new governance system from scratch. It's tying ANSI/HSI 2800 requirements to current enterprise programs, including ERM, cybersecurity, and quality improvement efforts.
| ANSI/HSI 2800 Element | NIST AI RMF Function | ISO/IEC 42001 Concept |
|---|---|---|
| Senior Ownership & Accountability | GOVERN | Leadership & Commitment |
| AI Use Case Inventory & Mapping | MAP | AI System Impact Assessment |
| Performance & Drift Monitoring | MEASURE | Performance Evaluation |
| Incident Response & Escalation | MANAGE | Nonconformity & Corrective Action |
| Vendor Transparency & BAA | GOVERN / MAP | Resources for AI Systems |
The aim is to fold AI governance into current risk and compliance workflows without duplicating them.
Risk Assessment for AI in Healthcare Operations
Evaluate Cyber, Operational, and Compliance Risk Together
Once ownership and inventory are set, the next move is simple: score what can go wrong. Governance and documentation matter, but they don't do the job on their own. AI needs a risk score before launch and across its full lifecycle.
ANSI/HSI 2800:2025 treats AI risk as a multi-domain issue. That means looking at cyber, operational, compliance, patient safety, and business continuity risk at the same time. If teams review those areas in isolation, they can miss how one tool creates several kinds of exposure at once. For example, a claims and coding tool can trigger upcoding liability, PHI exposure through a poorly scoped BAA, and automation bias if coders approve outputs without review [4][1].
That review should lead to a repeatable score, not a one-and-done checklist.
Use Consistent Risk Criteria Across AI Use Cases
Each AI tool is a little different. The outputs change. The users change. The failure points change. But the core risk factors stay the same.
ANSI/HSI 2800 supports a standardized scoring method that uses the same criteria across use cases: data sensitivity, level of autonomy, workflow criticality, and potential impact on care delivery or revenue [7][4]. Using those factors the same way across tools is what makes risk tiering defensible, both inside the organization and in front of auditors.
Apply the same scoring method to scheduling, coding, chatbots, prior authorization, and other operational tools.
| Operational AI Use Case | Key Risks | Related Governance Controls |
|---|---|---|
| Ambient Clinical Documentation | PHI leakage, inaccurate notes, automation bias | BAA with audio processing rights, clinician sign-off, patient opt-out [4] |
| Claims & Coding Assistance | Upcoding (False Claims Act exposure), revenue cycle drift | Human-in-the-loop review, statistical distribution audits, audit logs [4] |
| Patient Chatbots | Hallucinations, posing as a licensed professional | Disclosure of AI use, clinical oversight, language access checks [4][3] |
| Prior Authorization | Unfair denials, non-compliance with state restrictions | Algorithmic impact assessments, clinical outcome monitoring [3][6] |
| Appointment Scheduling | Inequitable access, incidental PHI exposure | Bias/equity impact assessments, vendor risk assessment, ERM integration [3][4] |
Fold AI Risk Reviews Into Enterprise Risk Management
The easiest path is to plug AI reviews into the risk systems you already use. AI risk findings should flow straight into current risk registers, third-party risk review workflows, and procurement gates. Use one risk path for each AI intake, then add AI-specific questions during vendor review.
When a new AI tool enters the process, it should trigger the same vendor review used for any third-party system that handles PHI, with extra AI-focused questions about model handling, subprocessors, and retention [8][4].
FDA clearance or vendor performance data does not replace local validation in your own population and environment [6]. A sepsis prediction model, for instance, can drift over time or behave differently after deployment. That's why it needs local validation, continuous monitoring, and clear pause thresholds [7][6]. Those local results then serve as the baseline for later monitoring and escalation thresholds.
From Principles to Practice Exploring AI Governance in Health Systems
sbb-itb-535baee
Vendor Controls, Data Governance, and Lifecycle Management
After risk scoring, contracts and data controls turn governance decisions into rules you can enforce.
Set Clear Vendor Requirements for AI Security and Transparency
Contracts should spell out who carries which risks. That usually means audit rights, required documentation, and clear limits on how data can be used. BAAs also need to match the actual use case. An ambient documentation tool and a claims coding tool may both touch PHI, but the data flows, subprocessors, and downstream use can look very different.
Ask vendors for an SBOM, a list of training data sources, stated exclusions, and known limits. For adaptive tools, require an authorized PCCP. As of 2025, only 10% of FDA-cleared or authorized AI/ML devices had an authorized PCCP [3]. That gap matters. It means model-change risk can still sit in the background with little control.
Govern Data Use, PHI Handling, and Audit Trails
Before deployment, define whether PHI will be used to train the model. Don't leave that vague. It should be written down, reviewed, and tied to the actual production setup.
Review BAAs both at signing and at renewal. That's a simple step, but it helps catch a common problem: the signed BAA no longer matches how data moves in production. Encryption at rest and in transit is a baseline requirement under 45 CFR 164.312 [4].
Access logs for model interactions and audit trails for AI-assisted decisions should also have set retention schedules that line up with HIPAA and internal record-retention rules. On top of that, quarterly sampled reviews of AI-generated outputs, like ambient notes or coded claims, can help spot accuracy drift and possible disparate impacts before they turn into compliance trouble.
Control the AI Lifecycle From Intake to Decommissioning
ANSI/HSI 2800:2025 expects a formal approval process across the full lifecycle, from intake through retirement. A good way to keep this from getting messy is to map each stage to one owner and one required artifact.
| Lifecycle Stage | Key Control Requirement | Required Evidence/Artifact | Internal Owner |
|---|---|---|---|
| Intake | Centralized AI Inventory | Documented list of all ML, GenAI, and agentic AI tools | CIO / IT |
| Validation | Local Clinical Validation | Performance report using internal patient data | CMIO / Clinical Lead |
| Procurement | AI-Specific BAA | Signed BAA with model training and subprocessor clauses | Legal / Privacy Officer |
| Deployment | Formal Committee Approval | Meeting minutes and signed approval charter | AI Governance Committee |
| Monitoring | Drift & Accuracy Tracking | Quarterly audit reports and performance dashboards | Quality Officer |
| Change Mgmt | Change Control (PCCP) | Authorized PCCP for adaptive algorithms | Technical AI Lead |
| Retirement | Decommissioning Plan | Documented triggers for tool removal | AI Governance Committee |
If a tool stops meeting safety or performance thresholds, there should be clear triggers for suspension or removal. You don't want teams making it up on the fly after a failure.
These controls only work when organizations also monitor performance, drift, and workflow impact after deployment.
Continuous Monitoring, Incident Response, and Near-Term Action Steps
After deployment, governance moves from approval to watchfulness and escalation. In practice, post-deployment monitoring is the control that closes the loop on earlier governance, risk scoring, vendor review, and lifecycle approval.
Monitor Performance, Drift, and Workflow Impact
Track performance, drift, outcomes, subgroup effects, and day-to-day workflow friction across three main clusters.
- Performance and outcomes: whether the predicted event actually occurred
- Equity: disparate impacts across racial, ethnic, or demographic subgroups
- Workflow disruption: staff over-reliance, staffing bottlenecks, scheduling delays, or revenue cycle slowdowns tied to AI-driven alerts
Set intervention thresholds ahead of time. That means naming the exact conditions that trigger a formal review, a pause, or decommissioning, so teams aren't forced to make judgment calls only after something has already gone wrong [6].
Prepare for AI-Related Incidents and Compliance Reviews
If monitoring surfaces a problem, the response should follow the same paths already used for incidents and downtime. Map AI incidents to current cyber incident, downtime, and vendor escalation playbooks. Keep AI audit logs and other required records ready for audit review.
AI incidents should be documented the same way other operational exceptions are documented. That keeps AI governance tied to normal hospital practice instead of turning it into a separate side process.
Under the FDA's Quality Management System Regulation (QMSR), which took full effect in January 2026, facilities must be able to produce Design History Files and post-market surveillance records for any regulated AI/ML device they deploy [5].
| Monitoring Activity | Responsible Role | Review Frequency | Required Documentation |
|---|---|---|---|
| Performance & Drift | Clinical/Operational Lead | Quarterly | Performance reports / drift logs |
| Bias & Equity Audit | Compliance/Equity Officer | Biannual | Algorithmic impact assessments |
| Security & Access | CISO / IT Security | Continuous | Access logs / security audit trails |
| Workflow Impact | Department Manager | Quarterly | Staff feedback / efficiency metrics |
| Adverse Events | Risk Management / Patient Safety | Real-time / As-needed | Incident reports / root cause analysis |
| Vendor Compliance | Procurement / Legal | Annual | Updated BAAs / SOC 2 reports |
| Audit Trail Integrity | Privacy Officer | Annually | 7-year log retention verification |
Conclusion: An Alignment Roadmap for Healthcare Leaders
ANSI/HSI 2800:2025 treats AI governance as a core enterprise risk, not just an IT project, and places oversight squarely within Board and executive accountability [1][2]. The standard reaches across the full lifecycle of AI in healthcare, from governance ownership and vendor controls to retirement decisions and post-deployment monitoring.
For leadership teams, the next step is practical, not abstract:
- AI use case inventory: Identify every tool in use, including EHR-embedded features and tools that slipped into workflows without formal approval [3][6].
- Governance ownership: Name an executive owner and create, or formalize, an AI governance committee with documented decision rights [1].
- Risk tiering: Use the same assessment criteria across AI use cases, separate clinical tools from operational ones, and tier them by risk level.
- Vendor evidence: Require updated BAAs and, for adaptive tools, an authorized PCCP before or at contract renewal [3][4].
- Centralized monitoring: Build a post-deployment monitoring program with defined thresholds, assigned roles, and documented review cycles [5][7].
Healthcare leaders can use these steps to line up AI governance, cut operational and cyber risk, and improve compliance.
Censinet RiskOps™ and Censinet AI™ are built to support this kind of scaled, human-guided implementation, helping healthcare organizations centralize AI risk assessments, manage vendor evidence, and keep the audit-ready documentation that ANSI/HSI 2800:2025 and regulators now expect.
FAQs
Who should own AI governance in a hospital?
A hospital’s Board of Directors holds the top-level responsibility for AI governance. The CEO and executive leadership team are then accountable for putting that governance into practice.
This work shouldn’t live in IT alone. AI affects the whole hospital. It brings both risk and upside, so governance needs input from executive leaders, technical experts, and frontline staff.
That shared oversight should cover the full process, including:
- procurement
- deployment
- monitoring
Just as important, staff need clear ways to escalate concerns when something looks off.
Does this standard apply to nonclinical AI tools too?
Yes. ANSI/HSI 2800:2025 is meant to help healthcare organizations use AI responsibly across clinical, administrative, and operational work.
That scope includes nonclinical tools used in day-to-day workflows - like revenue cycle, scheduling, and documentation - not just AI used for patient care.
What should organizations do first to align with the standard?
First, treat AI oversight as an enterprise risk and strategy issue, not just an IT project. That means the Board and executive leadership need to be involved from the start.
Then set up a formal, multidisciplinary governance committee with clear accountability and defined escalation paths. Rather than building a separate structure, weave those duties into existing quality, safety, and compliance processes.
